Trials@uspto.gov
571.272.7822

Paper 30
Date: January 13, 2026

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. FALK PHARMA GMBH,
Petitioner,

v.

ELLODI PHARMACEUTICALS, L.P.,
Patent Owner.

IPR2025-00052, Patent 10,632,069 B2
IPR2025-00054, Patent 11,246,828 B2
IPR2025-00055, Patent 9,486,407 B2
IPR2025-00056, Patent 11,260,061 B2[1]

Before JOHN G. NEW, ZHENYU YANG, and RYAN H. FLAX, *Administrative Patent Judges*.

FLAX, *Administrative Patent Judge*.

ORDER
Conduct of the Proceeding
Authorizing Patent Owner's Motion to Terminate
37 C.F.R. § 42.5(a)

[1] We use this caption for efficiency; these cases are not joined. The parties may not use such a caption without prior authorization from the Board.

In each of IPR2025-00052, IPR2025-00054, IPR2025-00055, and IPR2025-00056, Ellodi Pharmaceuticals, L.P. ("Patent Owner") is the owner of the respective challenged U.S. Patent, and Dr. Falk Pharma GMBH ("Petitioner") filed a respective Petition for *inter partes* review challenging the patentability of claims of that patent. The Board instituted trial in each of these *inter partes* review proceedings.

On January 13, 2026, Patent Owner emailed the Board stating:

> Patent Owner filed statutory disclaimers disclaiming all claims of the '069/'828/'407/'061 patents. Pursuant to 37 C.F.R. § 42.73(b)(1), Patent Owner requests adverse judgment with respect to the claims of the '069/'828/'407/'061 patents. As there are no remaining claims in the IPR2025-00052/54/55/56 proceedings, Patent Owner also requests authorization to file motions to terminate the proceedings. Petitioner does not oppose the motion.

Ex. 3002 (e.g., in IPR2025-0052).

Patent Owner's requests are authorized. Patent Owner is instructed to file the indicated statutory disclaimers as exhibits with the motion(s).

ORDER

Accordingly, it is hereby:

ORDERED that Patent Owner is authorized to file a motion to terminate, indicating its request for adverse judgment, in each of the above-captioned proceedings; and

FURTHER ORDERED that no other relief is granted.

IPR2025-00052, Patent 10,632,069 B2
IPR2025-00054, Patent 11,246,828 B2
IPR2025-00055, Patent 9,486,407 B2
IPR2025-00056, Patent 11,260,061 B2

For PETITIONER:

Nathanael Luman
Eric S. Furman
Jared C. Bunker
KNOBBE, MARTENS, OLSON, & BEAR, LLP
2nrl@knobbe.com
2esf@knobbe.com
2jcb@knobbe.com
BoxFalkPharma@knobbe.com

For PATENT OWNER:

Sanya Sukduang
Jonathan Cousin
Isha Agarwal
COOLEY LLP
ssukduang@cooley.com
jcousin@cooley.com
iagarwal@cooley.com
Ellodi_IPR@cooley.com